A popular drug approved by the FDA for weight loss also has heart benefits, according to a new study.
The drug, Wegovy, lowered the risk of major cardiovascular events by 20% in a clinical trial that included over 17,000 adults ages 45 and older who have a history of cardiovascular disease and are overweight or obese.
Without insurance coverage, the cost of Wegovy, a once a week injection, can run more than $1,000 a month. Novo Nordisk said the full findings of the SELECT clinical trial will be announced later this year at a medical conference.Jim Vondruska/Reuters
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Weiterlesen »
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Weiterlesen »
Wegovy drug reduces cardiovascular risks by 20%, says drugmakerA new study by drugmaker Novo Nordisk reveals that the weight-loss drug Wegovy has significantly reduced the risk of heart attack, stroke, and cardiovascular death in overweight adults with cardiovascular disease.
Weiterlesen »
Wegovy Reduces Risk of Stroke and Heart Attacks, According to CompanyThe weight-loss drug Wegovy has been found to have medical benefits beyond weight reduction, including reducing the risk of stroke and heart attacks. The results may lead to insurance companies providing coverage for the drug, which has previously been seen as a lifestyle medication.
Weiterlesen »
Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares SurgeNovo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
Weiterlesen »
Study: Weight-loss drug Wegovy cuts heart attack risk in those with obesityA recent study has found that the weight-loss drug Wegovy can significantly reduce the risk of heart attacks in individuals with obesity. This discovery could lead to an increased demand for the drug and strengthen the argument for insurance coverage. Experts emphasize that obesity should be treated as a serious illness due to its association with various health issues, including heart disease. However, private insurers have been hesitant to cover Wegovy, and Medicare is currently prohibited from covering weight-loss medications.
Weiterlesen »